Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT04234334 Completed - Clinical trials for Coronary Artery Disease

Benefits of Eggs in Combination With a Plant-based Diet

Start date: January 13, 2020
Phase: N/A
Study type: Interventional

The main objective of the study is to demonstrate that the inclusion of eggs to a plant-based diet will not increase the risk for heart disease but will increase the concentration of lutein and zeaxanthin, two important antioxidants and will also increase choline, an important component of membrane phospholipids.

NCT ID: NCT04232852 Withdrawn - Metabolic Syndrome Clinical Trials

Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk

Start date: June 12, 2019
Phase: N/A
Study type: Interventional

Metabolic Syndrome (MetS) and cardiovascular disease are associated with systemic inflammation (SI). Activation of the mechanisms of inflammation is triggered by the inflammatory cytokines. Τhe NLRP3 inflammasome is activated by microbial-derived low molecular weight (LMW) factors, short chain fatty acids (SCFAs), pathogen-associated molecular pattern molecules (PAMPs), damage-associated molecular pattern molecules (DAMPs), and monosodium urate crystals. Probiotics can regulate inflammation in two ways: 1) indirectly, by producing SCFAs as well as increasing synthesis of antimicrobial peptides and 2) directly, by binding innate immune system receptors Toll-like (TLR 2, 4, 9) and triggering important signaling pathways associated with activation of NLRs affecting the formation of inflammasome, thus the inflammatory response.

NCT ID: NCT04231838 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems

DIASMOKE
Start date: September 27, 2021
Phase: N/A
Study type: Interventional

Very little is known about the impact of combustion-free nicotine delivery systems (C-F NDS) on cardiovascular risk factors in T2DM patients who smoke. Data from clinical studies to identify any potential reduction in individuals' risk, relative to the risk of continued smoking, are needed. This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when T2DM patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products. The investigators propose a prospective 2-year multicenter randomized controlled trial (RCT) to evaluate changes in cardiovascular risk factors and functional parameters in diabetic smokers using C-F NDS and compared to those continuing cigarette smoking.

NCT ID: NCT04226014 Completed - Obesity Clinical Trials

Observational Cohort of Pancreatic Echo-endoscopy

OBELIX
Start date: July 17, 2018
Phase:
Study type: Observational

Metabolic syndrome is defined by the presence of at least two of the following five criteria: abdominal perimeter> 94 cm in men, 80 cm in women, high triglycerides, low HDL cholesterol, HTA and hyperglycemia. The metabolic syndrome can lead to ultrasound hepatic steatosis in 20 to 40% of cases depending on the population studied (overweight vs obesity). What is the impact of this syndrome on pancreatic echogenicity?

NCT ID: NCT04221152 Active, not recruiting - Clinical trials for Insulin Resistance Syndrome

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

EMPIRE-02
Start date: February 1, 2020
Phase: Phase 3
Study type: Interventional

A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.

NCT ID: NCT04216589 Completed - HIV Infections Clinical Trials

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Start date: February 19, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

NCT ID: NCT04208308 Recruiting - Metabolic Syndrome Clinical Trials

Omega-3 PUFA in Prevention of Cardiovascular and Metabolic Diseases (CARDMET3)

CARDMET3
Start date: January 15, 2013
Phase: Early Phase 1
Study type: Interventional

The study is aimed to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.

NCT ID: NCT04204538 Completed - Metabolic Syndrome Clinical Trials

Dietary Practices and Metabolic Syndrome in the Young Adult Population of Rwanda

NutriTransit
Start date: November 1, 2021
Phase:
Study type: Observational

Policy makers in Rwanda have recently highlighted the importance of promoting healthy diets and lifestyle in response to rapidly increasing rates of obesity. This project will provide evidence on shifts in diet and nutritional status in urban dwellers as compared to the traditional diet and lifestyle in rural areas as a basis for a targeted public health policy for Rwanda.

NCT ID: NCT04186767 Completed - Obesity Clinical Trials

Weight Loss Impact on Male Fertility

Start date: January 10, 2019
Phase: N/A
Study type: Interventional

This is a prospective non-randomized unicentric clinical trial, characterized by the inclusion of obese (BMI> 35) male with subfertility (sperm count showing low sperm counts and / or motility and / or morphology and / or DNA fragmentation). Patients selected at the endocrinology obesity HC-FMUSP outpatient will be submitted to very low calorie diet (VLCK) for 6 months, being reassessed clinically and laboratorially monthly.

NCT ID: NCT04183907 Completed - PreDiabetes Clinical Trials

Preventing Risk for Metabolic Syndrome in Workaholics: An Intervention

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Given the serious nature of the health risks workaholics face, it is important to understand how the health risks of workaholics can be mitigated. Blue Mesa Health (BMH), partner in this research, has developed a digital lifestyle intervention program, Transform, that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. The program's participants work to improve their diet and physical activity levels with the guidance of a smartphone app and a remote health coach. The researchers designed a study to examine if Transform is particularly effective for workaholics as compared to non-workaholics. The goal of this study is to test the effectiveness of Transform in improving workaholics' and non-workaholics' health and work outcomes.